{
    "organizations": [],
    "uuid": "143ae465cc03539d26afbcaea59c08ed9c827562",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-volitionrx-limited-announces-inter/brief-volitionrx-limited-announces-interim-results-from-680-subject-clinical-trial-in-colorectal-cancer-idUSASB0C7IE",
    "ord_in_thread": 0,
    "title": "BRIEF-Volitionrx Limited Announces Interim Results From 680-Subject Clinical Trial In Colorectal Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Volitionrx Ltd:\n* VOLITIONRX LIMITED ANNOUNCES INTERIM RESULTS FROM 680-SUBJECT CLINICAL TRIAL IN COLORECTAL CANCER\n* VOLITIONRX - ‍STUDY DEMONSTRATES HIGH DETECTION RATES OF STAGE I CANCER,PRE-CANCEROUS ADENOMAS IN COLORECTAL CANCER SCREENING TRIAL FOR NU.Q BLOOD TEST​\n* VOLITIONRX LTD - ‍DATA IS EXPECTED FROM 680-SUBJECT CLINICAL TRIAL IN 2018​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-27T05:22:00.000+02:00",
    "crawled": "2018-02-27T14:44:00.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "volitionrx",
        "ltd",
        "volitionrx",
        "limited",
        "announces",
        "interim",
        "result",
        "clinical",
        "trial",
        "colorectal",
        "cancer",
        "volitionrx",
        "demonstrates",
        "high",
        "detection",
        "rate",
        "stage",
        "cancer",
        "adenoma",
        "colorectal",
        "cancer",
        "screening",
        "trial",
        "blood",
        "volitionrx",
        "ltd",
        "expected",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}